Roche Seeks Diagnostics To Pair With Cancer Drugs In $3 Billion Ventana Bid
This article was originally published in The Gray Sheet
Executive Summary
Roche's $3 billion hostile takeover bid for Ventana Medical Systems is aimed at providing the drug and diagnostics giant with platform technology for tissue-based diagnostic tests to pair with targeted cancer drugs, the company says
You may also be interested in...
Roche Finally Gets Nod With Sweetened $3.4 Billion Bid For Ventana
After seven months and a half-dozen attempts at acquiring tissue-based cancer test maker Ventana Medical Systems, Roche finally won over the firm's board with a sweetened bid worth $3.4 billion
Roche Finally Gets Nod With Sweetened $3.4 Billion Bid For Ventana
After seven months and a half-dozen attempts at acquiring tissue-based cancer test maker Ventana Medical Systems, Roche finally won over the firm's board with a sweetened bid worth $3.4 billion
Ventana Invests In Project To Get Companion Diagnostics To Market
A new project underway at Arizona's Critical Path Institute (C-Path) will help the diagnostics industry and FDA coordinate efforts to streamline the regulatory path for tests used to personalize drug treatment